Sign inJoin waitlistJoin the waitlist

IM

Issam Makhoul

, Professor and Director of the Division of · University of Arkansas for Medical Sciences (UAMS) College of Medicine

Credentials: · · · ·

History

University of Arkansas for Medical Sciences (UAMS) College of Medicine
Present

Hematology and Medical Oncology
1983–1986
Internal Medicine
1980–1983
Doctor of Medicine
1976–1980

Research

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Systematic review or meta-analysis · Journal of Clinical Oncology · 2022 · 106 citations
In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma
Science Translational Medicine · 2019 · 104 citations
Mechanisms of bone metastases of breast cancer
Review · Endocrine Related Cancer · 2009 · Last of 3 authors · 97 citations

Jeanne Wei
10 papers
Suzanne Klimberg
10 papers
Angela Pennisi
9 papers · 7 as a fellow
Fade Mahmoud
8 papers
Konstantinos Arnaoutakis
8 papers
LH
Laura Hutchins
6 papers
AA
Ahmed Alwbari
4 papers · 1 as a fellow
Arif Kamal
4 papers
PM
Paulette Mehta
4 papers
Ronda Henry-Tillman
4 papers
Anne Chiang
3 papers
BS
Bradley Shields
3 papers

Grants

Clinical Cytophone Platform for Detection of Circulating Melanoma Cells.
National Cancer Institute · R41
PI · $298.8K · Cytoastra, Llc
2020–2023

Clinical trials

The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients
Principal investigator · Withdrawn · Phase 2
University of Arkansas
2021
Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer
Principal investigator · Terminated
University of Arkansas
2016–2021
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
Principal investigator · Terminated · Phase 2
University of Arkansas
2010–2019
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Principal investigator · Terminated · Phase 2
University of Arkansas
2006–2017